Recent Advances in the Clinical Application of Next-Generation Sequencing
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Next-generation sequencing (NGS) technologies have changed the process of genetic diagnosis from a gene-by-gene approach to syndrome-based diagnostic gene panel sequencing (DPS), diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). A priori information on the causative genes that might underlie a genetic condition is a prerequisite for genetic diagnosis before conducting clinical NGS tests. Theoretically, DPS, DES, and DGS do not require any information on specific candidate genes. Therefore, clinical NGS tests sometimes detect disease-related pathogenic variants in genes underlying different conditions from the initial diagnosis. These clinical NGS tests are expensive, but they can be a cost-effective approach for the rapid diagnosis of rare disorders with genetic heterogeneity, such as the glycogen storage disease, familial intrahepatic cholestasis, lysosomal storage disease, and primary immunodeficiency. In addition, DES or DGS may find novel genes that that were previously not linked to human diseases.
Abstract
Next-generation sequencing (NGS) technologies have changed the process of genetic diagnosis from a gene-by-gene approach to syndrome-based diagnostic gene panel sequencing (DPS), diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). A priori information on the causative genes that might underlie a genetic condition is a prerequisite for genetic diagnosis before conducting clinical NGS tests. Theoretically, DPS, DES, and DGS do not require any information on specific candidate genes. Therefore, clinical NGS tests sometimes detect disease-related pathogenic variants in genes underlying different conditions from the initial diagnosis. These clinical NGS tests are expensive, but they can be a cost-effective approach for the rapid diagnosis of rare disorders with genetic heterogeneity, such as the glycogen storage disease, familial intrahepatic cholestasis, lysosomal storage disease, and primary immunodeficiency. In addition, DES or DGS may find novel genes that that were previously not linked to human diseases.
참고문헌 (25)
- 이은실, "Identification of SLC26A3 Mutations in a Korean Patient with Congenital Chloride Diarrhea", Annals of Laboratory Medicine, 32(4), pp.312~315 (2012), 대한진단검사의학회[DOI]
- Choi M, "Genetic diagnosis by whole exome capture and massively parallel DNA sequencing", Proc Natl Acad Sci U S A, 106, pp.19096~19101 (2009)
- Adams DR, "Next-generation sequencing to diagnose suspected genetic disorders", N Engl J Med, 379, pp.1353~1362 (2018)
- Kim JH, "Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology of disorders of sex development", Mol Cell Endocrinol, 444, pp.19~25 (2017)
- Kim YM, "High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing", Clin Genet, 92, pp.594~605 (2017)
- Soo Hyun Nam, "Identification of Genetic Causes of Inherited Peripheral Neuropathies by Targeted Gene Panel Sequencing", Molecules and Cells, 39(5), pp.382~388 (2016), 한국분자세포생물학회
- Ko A, "Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy", Epilepsy Res, 141, pp.48~55 (2018)
- Rim JH, "Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing", BMC Med Genomics, 11, pp.6~ (2018)
- Han JY, "Targeted next-generation sequencing of Korean patients with developmental delay and", or intellectual disability, 2018, pp.6, 391~
- Rim JH, "Accuracy of next-generation sequencing for molecular diagnosis in patients with infantile nystagmus syndrome", JAMA Ophthalmol, 135, pp.1376~1385 (2017)
- Lee J, "Next-generation sequencing in Korean children with autism spectrum disorder and comorbid epilepsy", Front Pharmacol, 11, pp.585~ (2020)
- Ewans LJ, "Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders", Genet Med, 20, pp.1564~1574 (2018)
- Yang Y, "Clinical whole-exome sequencing for the diagnosis of mendelian disorders", N Engl J Med, 369, pp.1502~1511 (2013)
- Yang Y, "Molecular findings among patients referred for clinical whole-exome sequencing", JAMA, 312, pp.1870~1879 (2014)
- Lee H, "Clinical exome sequencing for genetic identification of rare Mendelian disorders", JAMA, 312, pp.1880~1887 (2014)
- Retterer K, "Clinical application of whole-exome sequencing across clinical indications", Genet Med, 18, pp.696~704 (2016)
- Meienberg J, "Clinical sequencing: is WGS the better WES?", Hum Genet, 135, pp.359~362 (2016)
- Marshall CR, "The Medical Genome Initiative : moving whole-genome sequencing for rare disease diagnosis to the clinic", Genome Med, 12, pp.48~ (2020)
- Lionel AC, "Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test", Genet Med, 20, pp.435~443 (2018)
- Ostrander BEP, "Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy", NPJ Genom Med, 3, pp.22~ (2018)
- Brewer MH, "Whole genome sequencing identifies a 78 kb insertion from chromosome 8 as the cause of Charcot-Marie-Tooth neuropathy CMTX3", PLoS Genet, 12, pp.e1006177~ (2016)
- Scocchia A, "Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico", NPJ Genom Med, 4, pp.5~ (2019)
- Vaz-Drago R, "Deep intronic mutations and human disease", Hum Genet, 136, pp.1093~1111 (2017)
- Di Scipio M, "Phenotype driven analysis of whole genome sequencing identifies deep intronic variants that cause retinal dystrophies by aberrant exonization", Invest Ophthalmol Vis Sci, 61, pp.36~ (2020)
- Larrue R, "Diagnostic utility of whole-genome sequencing for nephronophthisis", NPJ Genom Med, 5, pp.38~ (2020)